New York, USA, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Postpartum Depression Market to Exhibit Positive Growth During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market - Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited
The postpartum depression market is expected to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period.
DelveInsight’s Postpartum Depression Market Insights report includes a comprehensive understanding of current treatment practices, postpartum depression emerging drugs, market share of individual therapies, and current and forecasted postpartum depression market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Postpartum Depression Market Report
- As per DelveInsight’s analysis, the postpartum depression market size was found to be USD 260 million in 2022 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
- The market size captured by the United States was found to be the largest among the 7MM countries. In 2022, it was found that the United States accounted for ~64.6% of the total postpartum depression market size captured by the 7MM region.
- According to DelveInsight’s analysis, in 2022, the total diagnosed prevalent cases of PPD in mothers in the 7MM were ~1.1 million and these cases are anticipated to increase during the forecast period.
- Leading postpartum depression companies such as Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited, and others are developing novel postpartum depression drugs that can be available in the postpartum depression market in the coming years.
- Some of the key therapies for postpartum depression treatment include SAGE-217/BIIB-125, Ganaxolone, LPCN 1154, BRII-296, and others.
- Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy effectively treat PPD. Classes of medications are being prescribed for PPD as off-label therapies, such as selective serotonin reuptake inhibitors (SSRIs), a serotonin-norepinephrine reuptake inhibitors (SNRI). In March 2019, the US FDA approved ZULRESSO (brexanolone/SAGE-547), the first drug to treat adult PPD.
Discover which therapies are expected to grab the postpartum depression market share @ Postpartum Depression Market Report
Postpartum Depression Overview
Postpartum depression (PPD) stands as the most prevalent non-psychotic complication of childbirth, impacting around 10-15% of women. This condition represents a significant public health concern, affecting not only women but also their families. The postnatal period is widely recognized as a high-risk time for the emergence of severe mood disorders. Typically, postpartum depression manifests within 1 to 12 months after delivery. In certain cases, postpartum blues may persist and intensify. Common symptoms of postpartum depression include feelings of sadness, hopelessness, emptiness, and being overwhelmed. Women may also experience anxiety, irritability, oversleeping, anger, physical discomfort, and difficulties bonding with their babies. Identifying women at risk of postpartum depression during pregnancy is crucial to ensure timely follow-up and appropriate care.
Postpartum Depression Epidemiology Segmentation
The postpartum depression epidemiology section provides insights into the historical and current postpartum depression patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The postpartum depression market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Diagnosed Prevalent Population of Maternal Postpartum Depression
Download the report to understand which factors are driving postpartum depression epidemiology trends @ Postpartum Depression Epidemiological Insights
Postpartum Depression Treatment Market
Available treatments for postpartum depression include the utilization of antidepressant medications and emerging therapeutic methodologies centered around GABAA receptor modulation. Medical management for PPD encompasses multiple facets, including interventions for depression, anxiety disorders, substance abuse, and psychological approaches for eating disorders. This treatment strategy also encompasses psychological and psychosocial therapies, in addition to non-pharmacological interventions. Moreover, the comprehensive care of a patient with PPD and their family necessitates the establishment of a support system to nurture their psychosocial health.
Antidepressants, including ABILIFY (aripiprazole), ZOLOFT (sertraline hydrochloride), SPRAVATO (esketamine), PROZAC (fluoxetine capsules), CELEXA (citalopram hydrobromide), LUVOX CR (Fluvoxamine Maleate), and PAXIL CR (paroxetine), are the primary pharmacological interventions for addressing postpartum depression. Although these medications are officially indicated for conditions like major depressive disorder, obsessive-compulsive disorder, and post-traumatic stress disorder, they are also used off-label for PPD treatment.
At present, the sole available product on the market for treating patients with postpartum depression is ZULRESSO (brexanolone/SAGE-547). This medication, produced by Sage Therapeutics, received approval from the US FDA in March 2019. ZULRESSO is classified as a neuroactive steroid gamma-aminobutyric acid (GABAA) receptor-positive modulator and stands as the first and exclusive treatment specifically designed for addressing PPD. Administered via continuous intravenous infusion over 2.5 days, it requires supervision by healthcare providers at certified sites of care under the ZULRESSO Risk Evaluation and Mitigation Strategy (REMS) program. The one-time infusion demonstrates the potential for swiftly alleviating depressive symptoms associated with PPD.
Learn more about the FDA-approved drugs for postpartum depression @ Drugs for Postpartum Depression Treatment
Key Postpartum Depression Therapies and Companies
- SAGE-217/BIIB-125: Sage Therapeutics/Biogen
- Ganaxolone: Marinus Pharmaceuticals
- LPCN 1154: Lipocine
- BRII-296: Brii Biosciences Limited
To know more about postpartum depression clinical trials, visit @ Postpartum Depression Treatment Drugs
Postpartum Depression Market Dynamics
The postpartum depression market dynamics are anticipated to change in the coming years. ZULRESSO’s rapid onset of action within 2–3 days significantly enhances response rates in contrast to conventional therapies. As drugs such as BRII-296 and LPCN-1154 remain in the early stages of clinical development, their potential approval in the future holds promise for substantial growth in the PPD therapeutic market. The scarcity of available treatments for diagnosing and addressing PPD creates profitable openings for emerging therapies. The increased focus on research and development to comprehend the pathophysiology, along with recent diagnostic advancements, presents a lucrative opportunity for the expansion of the PPD market.
Furthermore, many potential therapies are being investigated for the treatment of postpartum depression, and it is safe to predict that the treatment space will significantly impact the postpartum depression market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the postpartum depression market in the 7MM.
However, several factors may impede the growth of the postpartum depression market. The diagnosis of PPD becomes challenging due to its symptoms being similar to other depressive disorders. This difficulty arises from the absence of a standardized screening method, inconsistent data collection, and the lack of consistent cut-off scores on diagnostic instruments, complicating the identification of PPD. Additionally, the availability of off-label, more affordable antidepressants might disrupt emerging therapies in the market. Administering ZULRESSO through a prolonged 60-hour IV infusion could potentially reduce patient compliance, while patients treated with ZULRESSO face risks of excessive sedation or sudden loss of consciousness during its administration.
Moreover, postpartum depression treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the postpartum depression market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the postpartum depression market growth.
| Postpartum Depression Report Metrics | Details |
| Study Period | 2019–2032 |
| Postpartum Depression Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Postpartum Depression Market Size in 2022 | USD 260 Million |
| Key Postpartum Depression Companies | Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited, and others |
| Key Postpartum Depression Therapies | SAGE-217/BIIB-125, Ganaxolone, LPCN 1154, BRII-296, and others |
Scope of the Postpartum Depression Market Report
- Postpartum Depression Therapeutic Assessment: Postpartum Depression current marketed and emerging therapies
- Postpartum Depression Market Dynamics: Attribute Analysis of Emerging Postpartum Depression Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Postpartum Depression Market Access and Reimbursement
Discover more about postpartum depression drugs in development @ Postpartum Depression Clinical Trials
Table of Contents
| 1. | Postpartum Depression Market Key Insights |
| 2. | Postpartum Depression Market Report Introduction |
| 3. | Postpartum Depression Market Overview at a Glance |
| 4. | Postpartum Depression Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Postpartum Depression Treatment and Management |
| 7. | Postpartum Depression Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Postpartum Depression Marketed Drugs |
| 10. | Postpartum Depression Emerging Drugs |
| 11. | Seven Major Postpartum Depression Market Analysis |
| 12. | Postpartum Depression Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Postpartum Depression Epidemiology Forecast
Postpartum Depression Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted postpartum depression epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Postpartum Depression Pipeline
Postpartum Depression Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key postpartum depression companies, including Sage Therapeutics, Epharmix, Inc., among others.
Treatment-Resistant Depression Pipeline
Treatment-Resistant Depression Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key treatment-resistant depression companies, including Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, among others.
Bipolar Depression Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bipolar depression companies, including Vanda Pharmaceuticals, Reviva Pharmaceuticals, SK BIOPHARMACEUTICALS, Pear Therapeutics, Arvelle Therapeutics, Janssen Research & Development, Sunovion Pharmaceuticals, Lyndra Therapeutics, ILTOO Pharma, COMPASS Pathways, NRx Pharmaceuticals, Carlsson Research AB, Sunovion, SAGE Therapeutics, Alzamend Neuro, OWP Pharmaceuticals, Entheogenix Biosciences, among others.
Hot Flashes Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key hot flashes companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
